Markus Cybulla

Dr. Markus Cybulla

Deutsche Gesellschaft für Nephrologie, Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2006 in Annals of the New York Academy of Sciences
Verified
Journal Article
Open access
PDF file
BBBirke Bausch
Birke Bausch
CBCarsten C. Boedeker
Carsten C. Boedeker
ABAnsgar Berlis
Ansgar Berlis
IBIngo Brink
Ingo Brink
MCMarkus Cybulla
Markus Cybulla
HNHartmut P.H. Neumann
Hartmut P.H. Neumann
Abstract:  Although deceptively simple, the etio‐pathogenesis of pheochromocytoma represents a clinical and molecular genetic investigative challenge. Here, we summarize, from a historical point of view, the 22‐year‐long studies initiated at the University of Freiburg, which developed from a local experience to a national and finally an international effort. All research activities are translational and clinical and hence, registry based and intended to improve the outcome of the patients, whether by improved detection, prevention, or treatment. Major clinical steps are the prospective study on hormone tests and imaging techniques for adrenal and extra‐adrenal abdominal tumors as well as the concept of organ sparing and endoscopic tumor resection. Further, we introduced 18‐fluoro‐dopa positron emission tomography. Population‐based registries were used in order to identify germline mutations in the susceptibility genes VHL, RET, SDHB, and SDHD in non‐syndromic pheochromocytoma. We differentiated distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Finally, we identified predictors and prevalence of paraganglioma syndromes associated with mutations of the SDHC gene.

17 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MCMarkus Cybulla
Markus Cybulla
KNKathleen Nicholls
Kathleen Nicholls
SFSandro Feriozzi
Sandro Feriozzi
ALAleš Linhart
Aleš Linhart
JTJuan Torras
Juan Torras
MWMichael Lindsay West
Michael Lindsay West
Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, which, without treatment, can cause significant renal dysfunction. We evaluated the effects of enzyme replacement therapy with agalsidase alfa on renal decline in patients with Fabry disease using data from the Fabry Outcome Survey (FOS) registry. Male patients with Fabry disease aged >16 years at agalsidase alfa start were stratified by low (≤0.5 g/24 h) or high (>0.5 g/24 h) baseline proteinuria and by ‘classic’ or ‘non-classic’ phenotype. Overall, 193 male patients with low (n = 135) or high (n = 58) baseline proteinuria were evaluated. Compared with patients with low baseline proteinuria, those with high baseline proteinuria had a lower mean ± standard deviation baseline eGFR (89.1 ± 26.2 vs. 106.6 ± 21.8 mL/min/1.73 m2) and faster mean ± standard error eGFR decline (−3.62 ± 0.42 vs. −1.61 ± 0.28 mL/min/1.73 m2 per year; p < 0.0001). Patients with classic Fabry disease had similar rates of eGFR decline irrespective of baseline proteinuria; only one patient with non-classic Fabry disease had high baseline proteinuria, preventing meaningful comparisons between groups. In this analysis, baseline proteinuria significantly impacted the rate of eGFR decline in the overall population, suggesting that early treatment with good proteinuria control may be associated with renoprotective effects.

1 November 2007 in Spektrum der Augenheilkunde
Verified
Journal Article
Closed access
PDF file
HNH. P. H. Neumann
H. P. H. Neumann
MCMarkus Cybulla
Markus Cybulla
SGS. Gläsker
S. Gläsker
CCC. Coulin
C. Coulin
VVV. Van Velthoven
V. Van Velthoven
CBC. C. Boedeker
C. C. Boedeker